Position in NVO
as of Jun 30, 2026
· filed Jul 22, 2026
Position Value
$3,745,743
+$748,266 QoQ
Shares Held
78,134
-4.2% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.86%
of 13F equity value
Holder Rank
#258
of 1,348 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 10%
Shared 0%
None 90%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026MARATHON CAPITAL MANAGEMENT holds $31,900,311 across 10 Drug Manufacturers - General names. NVO ranks #3 (11.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
64,777 | $12,283,014 | |
| 2 | JNJ |
Johnson & Johnson
|
25,121 | $6,379,980 | |
| 3 | NVO |
Novo Nordisk A S
This page
|
78,134 | $3,745,743 | |
| 4 | MRK |
Merck & Co., Inc.
|
23,351 | $3,000,603 | |
| 5 | LLY |
ELI LILLY & Co
|
2,492 | $2,988,979 | |
| 6 | ABBV |
AbbVie Inc.
|
6,807 | $1,712,913 | |
| 7 | AMGN |
Amgen Inc
|
2,533 | $917,249 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
8,325 | $479,686 |
All Filings in NVO
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,745,743 | 78,134 | Shares | Sole | 2026-07-22 | |
| 2026-03-31 | $2,997,477 | 81,564 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $4,208,030 | 82,705 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $3,189,287 | 57,475 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||